The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Digital Health Market: Focus on Digital Therapeutic, Monitoring and Diagnostic Solutions, 2018-2030

  • Lowest Price Guaranteed From USD 3,499

  • Published
    July 2018

  • Pages
    432

  • View Count
    4620

Example Insights

 

Overview

There is a lot of excitement in terms of VC funding and large number of entrepreneurs are raising money in this sector. Most of the recent funding has gone into later stage financing, demonstrating how the field has matured and the progress that the companies have made

-Chief Executive Officer, US based digital therapeutics company

Chronic disorders, such as diabetes, heart disease, obesity, mental health problems and insomnia, are considered to be the leading causes of death and disability across the world. These are largely considered to be the consequence of unhealthy lifestyle choices and exposure to harmful disease stimulants. According to a 2018 report published by the Center for Managing Chronic Disease at the University of Michigan, more than 50% of the global population currently lives with some form of chronic disease. Projections indicate that the global prevalence of diabetes (considered to be one of the fastest-growing chronic disease indications), is around 451 million, and is expected to reach 693 million by 2025. In addition, the World Health Organization (WHO) estimates that, at present, 450 million people worldwide are suffering from some form of mental health problem and / or neurological disorder. The increasing prevalence of such clinical conditions has imposed a significant burden on the modern healthcare system. In the US, the cost burden related to such long-term clinical conditions has been estimated to be approximately 86% of the USD 3.2 trillion that is spent by the country on healthcare, each year.

Digital healthcare, a relatively new concept that emerged only a few years ago, is believed to possess the potential to address the rising concerns related to the growing socio-economic burden. Driven by the demand for self-management approaches, personalized healthcare solutions and customized treatment regimens made available in the home-care setting, digital health companies are presently engaged in developing several innovative solutions for therapeutic, surveillance and diagnostic use. Various digital therapeutics, through behavioral and psychological interventions, have been designed to have a direct impact on the chronic clinical conditions by providing motivational support and encouraging patients to make better lifestyle choices. Such therapeutics are available in a variety of gaming solutions, standalone software applications or combinations of the aforementioned solutions with personal coaching support, artificial intelligence (AI) support and medical device(s). A number of digital therapeutics have already been marketed and a significant proportion of such candidate therapies are in R&D phase. In order to introduce such unconventional products into the market, companies have followed multiple approaches, which include both B2B and B2C variants. It is also worth highlighting that certain companies are even attempting to offer reimbursements for their proprietary products by conducting clinical trials in order to establish therapeutic credibility and convince insurance providers and payers.

Significant advancements have also been made towards the development of novel solutions for remote monitoring and diagnosis of chronic disorders. Such solutions have been developed to provide healthcare assistance in real-time through smartphone applications and connected devices. These solutions vary significantly in complexity and range from simple solutions capable of tracking weight loss, blood pressure, body temperature and heart rate to more sophisticated solutions that are equipped to independently conduct blood tests to confirm the presence of a bacterial / viral infection.

 

Scope of the Report

The ‘Digital Health Market: Focus on Digital Therapeutic, Monitoring & Diagnostic Solutions, 2018-2030’ report features an extensive study of the current landscape and future outlook of the growing market for digital therapeutics, monitoring and diagnostic solutions that are either commercialized or under development within the healthcare industry. This burgeoning field presently offers a lot of opportunities to innovation focused start-ups and investors. Amongst other elements, the report features:

  • A discussion on the current market landscape of digital therapeutics, monitoring and diagnostic solutions, featuring information on the various developers of digital solutions, along with information on their type of solution offered, primary disease area, mechanism of action, purpose of solution, status of development (discovery, research / development, approved and marketed), launch year (if applicable) and business channels being used by stakeholders in this domain.
  • Detailed profiles of some of the emerging players in the industry, highlighting their current focus area(s), information on digital solutions offered and clinical research results (wherever available). Each profile also includes a section on recent developments and a comprehensive future outlook, highlighting the achievements, partnerships / collaborations, and the likely strategies that may be adopted by these players for future growth.
  • A comprehensive product competitiveness analysis of digital therapeutics for the most popular therapeutic areas taking into consideration the product portfolio (based on the total number of digital therapeutics being developed in that disease area) and key specifications of the solution, such as disease management support, user motivation features, tracking of health data and others.
  • A case study highlighting the focus area and results of clinical trials that have been conducted for the evaluation of various digital therapeutics.
  • An analysis of funding and investments made into companies involved in this segment of the overall healthcare industry; the analysis covers information on seed financing, venture capital financing, debt financing, other equity financing and grants / awards received by these companies.
  • An analysis of the partnerships that have been forged between companies in this domain in the recent past, covering clinical trial collaborations, product development and commercialization agreements, pilot product offerings, product integration and other relevant agreements.
  • A detailed case study highlighting the various business models and go-to-market strategies adopted by companies involved in this space. It provides details on various channels being adopted by stakeholders in the industry to increase awareness and offer access to their proprietary products.
  • A SWOT analysis capturing the key parameters and trends that are likely to influence the future of digital therapeutics market.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on multiple parameters, such as prices of digital solutions, indication / region specific adoption trends, distribution channels and competitive landscape, we have provided an informed estimate on the likely evolution of digital therapeutics and digital monitoring / diagnostic solutions till 2030. We have segmented the market by therapeutic areas (such as metabolic disorders, mental health disorders, cardiovascular disorders, substance use disorders, neurological disorders, chronic pain disorders, sleep disorders and respiratory disorders), distribution channels (B2C (patients) and B2B (healthcare providers, payers, employers and pharmaceutical companies)), purpose of solution (therapeutic or preventive), focus of solution (medication replacement or medication augmentation), type of solution (standalone software applications and software application + device or AI or personal coach) and key regions across the globe (North America (the US and Canada), Europe (Germany, France, Italy, the UK, Russia, and Spain), Asia-Pacific (China, Japan, India, Australia and South Korea) and rest of the world. In order to account for the uncertainties associated with the development of digital therapeutics and novel diagnostic / monitoring solutions and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with Adam Kaufman (Canary Health), Amelie Janson (Voluntis), Prayat Shah (Co-founder, Vice President, Partnerships, Wellthy Therapeutics) and Reshma Nayak (Vice President, Marketing and Communications, Wellthy Therapeutics), Stephanie Tilenius (Vida Health) and Vijay Ravindran (Floreo). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the digital therapeutics, monitoring and diagnostic solutions market in the mid to long term.

Chapter 3  provides a general overview of the digital health sector, covering details related to the current and future trends affiliated to the domain. The chapter highlights key concepts involved in the development of digital therapeutics. It also features a discussion on strategic initiatives undertaken by several organizations to support the development of digital solutions for treatment of chronic disorders. The chapter also provides an overview of the various product development pathways adopted by the companies in this field. 

Chapter 4  includes information on over 100 digital therapeutics and close to 60 novel digital monitoring / diagnostic solutions that are currently being evaluated across different stages of development. The chapter features a comprehensive analysis of digital solutions, highlighting the target therapeutic areas, phases of development, type of solution, purpose of solution, and business models adopted for their marketing / sales. In addition, we have presented a comprehensive grid analysis of various digital solutions, highlighting their respective target therapeutic area, type of solution and phases of development. Further, the chapter features a dot-plot analysis of the most active players in the digital therapeutics sector, taking into consideration the status of development of various solutions and company’s current product portfolio specific to digital health. 

Chapter 5  features detailed profiles of some of the emerging stakeholders that are offering digital therapeutics solutions for patients suffering from various types of chronic disorders. Each profile includes an overview of the company, details related to its digital solutions, clinical trial results, recent developments and a comprehensive future outlook.

Chapter 6  includes detailed profiles of some of the emerging stakeholders that are offering digital solutions for monitoring or diagnosis of various types of chronic conditions. Each profile includes an overview of the company, details related to its digital solutions, recent developments and a comprehensive future outlook.

Chapter 7  presents a product competitiveness analysis of digital therapeutics on the basis of their respective target therapeutic areas. The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 8  is a case study on the clinical trials that were / are being conducted for the evaluation of digital therapeutics. The chapter provides an overview of the specific objectives of the aforementioned studies of digital interventions intended for use by patients suffering from chronic disease indications. It features brief information on the study end-points as well.

Chapter 9  provides information on the funding instances and investments that have been made in both digital therapeutics and novel digital monitoring / diagnostics space. The chapter includes details on various investments (such as seed financing, venture funding, debt financing and grants) received by companies till May 2018, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 10  features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including pilot product offerings, product integration agreements, marketing and distribution agreements, product development agreements, product evaluation agreements, research and development agreements, acquisition agreements, product launch agreements, technology licensing agreements, product licensing agreements, clinical trial agreements and others ) and the most common forms of deals / agreements that have been established in the period between 2011 and 2018, in this field. 

Chapter 11  features a detailed case study highlighting the go-to-market strategies adopted by companies engaged in this space. It presents insightful information on important marketing strategies, such as inbound marketing through social media platforms, promotional activities through official websites, business models and pricing models used by various players in the market. 

Chapter 12  presents a comprehensive market forecast, highlighting the future potential of the market till 2030 based on multiple parameters, such as prices of digital solutions, indication / region specific adoption trends, distribution channels and competitive landscape. We have provided an informed estimate on the likely evolution of digital therapeutics and digital monitoring / diagnostic solutions. In addition, we have segmented the market by therapeutic areas (such as metabolic disorders, mental health disorders, cardiovascular disorders, substance use disorders, neurological disorders, chronic pain disorders, sleep disorders and respiratory disorders), distribution channels (B2C (patients) and B2B (healthcare providers, payers, employers and pharmaceutical companies)), purpose of solution (therapeutic or preventive), focus of solution (medication replacement or medication augmentation), type of solution (standalone software applications and software application + device or AI or personal coach) and key regions across the globe (North America (the US and Canada), Europe (Germany, France, Italy, the UK, Russia, and Spain), Asia-Pacific (China, Japan, India, Australia and South Korea) and rest of the world.

Chapter 13  presents a detailed discussion on the future opportunities of digital solutions for chronic disease management. It  also highlights the key parameters and trends that are likely to influence the future of this market, under a comprehensive SWOT framework.

Chapter 14  is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Adam Kaufman (Canary Health), Amelie Janson (Voluntis), Prayat Shah (Co-founder, Vice President, Partnerships, Wellthy Therapeutics) and Reshma Nayak (Vice President, Marketing and Communications, Wellthy Therapeutics), Stephanie Tilenius (Vida Health) and Vijay Ravindran (Floreo).

Chapter 15  is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16  is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Digitization in Healthcare Sector
3.2. Next-Generation Healthcare Solutions
3.3. Key Concepts Associated with Digital Health Solutions
3.3.1. Cognitive Behavioral Therapy
3.3.2. Internet of Things
3.3.3. Big Data
3.3.4. Artificial Intelligence
3.3.5. Gamification
 
3.4. An Overview of Digital Therapeutics
3.4.1. Key Strategic Initiatives
3.4.1.1. Digital Therapeutics Alliance
3.4.1.2. Personal Connected Health Alliance
3.4.1.3. Programs Initiated by The Centers for Disease Control and Prevention
3.4.1.4. HIPAA Act
3.4.1.5. National Health Service Guidelines
3.4.1.6. USFDA Regulations for Digital Therapeutics
 
3.4.2. Typical Development and Commercialization Pathway for Digital Therapeutics
3.4.2.1. Discovery and Preclinical Phase
3.4.2.2. Clinical Trials and Validation
3.4.2.3. Negotiation with Insurance Providers / Payers
3.4.2.4. Distribution and Marketing
 
3.4.3. Rising Popularity of Digital Therapeutics
3.5. Remote Digital Monitoring and Diagnosis
 
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Therapeutics: Overall Market Landscape
4.2.1. Distribution by Year of Establishment of Developer
4.2.2. Distribution by Geographical Location of Developer
4.2.3. Distribution by Size of Developer
4.2.4. Distribution by Type of Solution
4.2.5. Distribution by Primary Disease Area
4.2.6. Distribution by Therapeutic Area
4.2.7. Distribution by Purpose of Solution
4.2.8. Distribution by Focus of Solution
4.2.9. Distribution by Status of Development
4.2.10. Distribution of Type of Business Model
4.2.11. Grid Analysis
4.2.12. Dot Plot Analysis for Most Active Players
 
4.3. Digital Monitoring / Diagnostic Solutions: Overall Market Landscape
4.3.1. Distribution by Year of Establishment of Developer
4.3.2. Distribution by Geographical Location of Developer
4.3.3. Distribution by Size of Developer
4.3.4. Distribution by Type of Solution
4.3.5. Distribution by Primary Disease Area
4.3.6. Distribution by Therapeutic Area
4.3.7. Distribution by Status of Development
4.3.8 Grid Analysis
 
5. DIGITAL THERAPEUTICS: COMPANY PROFILES
5.1. Chapter Overview
 
5.2. 2Morrow
5.2.1 Company Snapshot
5.2.2. Product Portfolio
5.2.3. Research Studies and Scientific Evidence
5.2.4. Recent Developments and Future Outlook
 
5.3. Akili Interactive
5.3.1. Company Snapshot
5.3.2. Product Portfolio
5.3.3. Research Studies and Scientific Evidence
5.3.4. Recent Developments and Future Outlook
 
5.4. Canary Health
5.4.1. Company Snapshot
5.4.2. Product Portfolio
5.4.3. Research Studies and Scientific Evidence
5.4.4. Recent Developments and Future Outlook
 
5.5 Floreo
5.5.1. Company Snapshot
5.5.2. Product Portfolio
5.5.3. Research Studies and Scientific Evidence
5.5.4. Recent Developments and Future Outlook
 
5.6. Omada Health
5.6.1. Company Snapshot
5.6.2. Product Portfolio
5.6.3. Research Studies and Scientific Evidence
5.6.4. Recent Developments and Future Outlook
 
5.7. Pear Therapeutics
5.7.1. Company Snapshot
5.7.2. Product Portfolio
5.7.3. Research Studies and Scientific Evidence
5.7.4. Recent Developments and Future Outlook
 
5.8. Vida Health
5.8.1. Company Snapshot
5.8.2. Product Portfolio
5.8.3 Research Studies and Scientific Evidence
5.8.4. Recent Developments and Future Outlook
 
5.9. WellDoc
5.9.1. Company Snapshot
5.9.2. Product Portfolio
5.9.3. Research Studies and Scientific Evidence
5.9.4. Recent Developments and Future Outlook
 
5.10. Wellthy Therapeutics
5.10.1. Company Snapshot
5.10.2. Product Portfolio
5.10.3. Research Studies and Scientific Evidence
5.10.4. Recent Developments and Future Outlook
 
6. DIGITAL MONITORING / DIAGNOSTIC SOLUTIONS: COMPANY PROFILES
6.1. Chapter Overview
 
6.2. AliveCor
6.2.1. Company Snapshot
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
 
6.3. BioSerenity
6.3.1. Company Snapshot
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
 
6.4. Cue
6.4.1. Company Snapshot
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook
 
6.5. Kinsa
6.5.1. Company Snapshot
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook
 
6.6. Voluntis
6.6.1. Company Snapshot
6.6.2. Product Portfolio
6.6.2.1. Digital Therapeutic Solutions
6.6.2.2. Digital Monitoring Solutions
6.6.3. Recent Developments and Future Outlook
 
7. KEY INSIGHTS: PRODUCT COMPETITIVENESS ANALYSIS AND MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Key Therapeutic Areas
7.2.1. Metabolic Disorders
7.2.1.1. Market Landscape
7.2.1.2. Product Competitiveness Analysis
 
7.2.2. Mental Health Problems
7.2.2.1. Market Landscape
7.2.2.2. Product Competitiveness Analysis
 
7.2.3. Neurological Disorders
7.2.3.1. Market Landscape
7.2.3.2. Product Competitiveness Analysis
 
7.2.4. Other Therapeutic Areas
 
8. DIGITAL THERAPEUTICS: CLINICAL RESEARCH EVIDENCE
8.1. Chapter Overview
8.2. Digital Therapeutics: Clinical Trials Data
8.3. Digital Therapeutics: Clinical Trials Data: Distribution by Therapeutic Areas
8.4. Digital Therapeutics: Clinical End-Points Analysis: Metabolic Disorders
 
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Digital Therapeutics: Funding and Investment Analysis
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Most Active Players in terms of Number of Instances
9.3.5. Most Active Players in terms of Amount of Funding
9.3.6. Most Active Investors in terms of Number of Instances
 
9.4. Digital Monitoring / Diagnostic Solutions: Funding and Investment Analysis
9.4.1. Analysis by Number of Funding Instances
9.4.2. Analysis by Amount Invested
9.4.3. Analysis by Type of Funding
9.4.4. Most Active Players in terms of Number of Instances
9.4.5. Most Active Players in terms of Amount of Funding
9.4.6. Most Active Investors in terms of Number of Instances
 
10. COLLABORATIONS AND PARTNERSHIPS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Digital Therapeutics and Monitoring / Diagnostic Solutions: Recent Collaborations and Partnerships
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Most Active Players
 
11. GO-TO-MARKET STRATEGY
11.1. Chapter Overview
11.2. Digital Therapeutic Developers: Marketing Strategies
11.2.1. Participation in Global Events
11.2.2. Marketing on Social Media Platforms
11.2.3. Marketing on Online / Print Media Platforms
 
11.2.4. Adoption of Different Business Models and Pricing Strategies
11.2.4.1. B2C Business Model
11.2.4.2. B2B Business Model
11.2.4.3. Pricing Strategy
11.2.5. Undertaking Various Promotional Activities
11.3. Concluding Remarks
 
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Digital Therapeutics Market, 2018-2030
 
12.4. Global Digital Therapeutics Market: Distribution by Type of Solution
12.4.1. Digital Therapeutics Market for Standalone Software Applications, 2018-2030
12.4.2. Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2018-2030
12.4.3. Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2018-2030
12.4.4. Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2018-2030
12.4.5. Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2018-2030
12.4.6. Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2018-2030
12.4.7. Digital Therapeutics Market for Other Type of Solutions, 2018-2030
 
12.5. Global Digital Therapeutics Market: Distribution by Focus of Solution
12.5.1. Digital Therapeutics Market for Medication Replacement Solutions, 2018-2030
12.5.2. Digital Therapeutics Market for Medication Augmentation Solutions, 2018-2030
 
12.6. Global Digital Therapeutics Market: Distribution by Purpose of Solution
12.6.1 Digital Therapeutics Market for Therapeutic Solutions, 2018-2030
12.6.2. Digital Therapeutics Market for Preventive Solutions, 2018-2030
 
12.7. Global Digital Therapeutics Market: Distribution by Business Model
12.7.1. Digital Therapeutics Market for B2C Model (Patients), 2018-2030
12.7.2. Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2018-2030
 
12.8. Global Digital Therapeutics Market: Distribution by Geography
12.8.1 Digital Therapeutics Market in North America, 2018-2030
12.8.1.1 Digital Therapeutics Market in the US, 2018-2030
12.8.1.2 Digital Therapeutics Market in Canada, 2018-2030
12.8.2 Digital Therapeutics Market in Europe, 2018-2030
12.8.2.1. Digital Therapeutics Market in Germany, 2018-2030
12.8.2.2. Digital Therapeutics Market in France, 2018-2030
12.8.2.3. Digital Therapeutics Market in Russia, 2018-2030
12.8.2.4. Digital Therapeutics Market in Italy, 2018-2030
12.8.2.5. Digital Therapeutics Market in the UK, 2018-2030
12.8.2.6. Digital Therapeutics Market in Spain, 2018-2030
12.8.2.7. Digital Therapeutics Market in Rest of Europe, 2018-2030
 
12.8.3. Digital Therapeutics Market in Asia-Pacific, 2018-2030
12.8.3.1. Digital Therapeutics Market in China, 2018-2030
12.8.3.2. Digital Therapeutics Market in Japan, 2018-2030
12.8.3.3. Digital Therapeutics Market in India, 2018-2030
12.8.3.4. Digital Therapeutics Market in Australia, 2018-2030
12.8.3.5. Digital Therapeutics Market in South Korea, 2018-2030
12.8.3.6. Digital Therapeutics Market in Rest of Asia-Pacific, 2018-2030
 
12.8.4. Digital Therapeutics Market in Rest of the World, 2018-2030
 
12.9. Global Digital Therapeutics Market: Distribution by Therapeutic Area
12.9.1. Digital Therapeutics Market for Metabolic Disorders, 2018-2030
12.9.1.1. Digital Therapeutics Market for Metabolic Disorders in North America, 2018-2030
12.9.1.2. Digital Therapeutics Market for Metabolic Disorders in Europe, 2018-2030
12.9.1.3. Digital Therapeutics Market for Metabolic Disorders in Asia-Pacific, 2018-2030
12.9.1.4. Digital Therapeutics Market for Metabolic Disorders in Rest of the World, 2018-2030
 
12.9.2. Digital Therapeutics Market for Mental Health Problems, 2018-2030
12.9.2.1. Digital Therapeutics Market for Mental Health Problems in North America, 2018-2030
12.9.2.2. Digital Therapeutics Market for Mental Health Problems in Europe, 2018-2030
12.9.2.3. Digital Therapeutics Market for Mental Health Problems in Asia-Pacific, 2018-2030
12.9.2.4. Digital Therapeutics Market for Mental Health Problems in Rest of the World, 2018-2030
 
12.9.3. Digital Therapeutics Market for Substance Use Disorders, 2018-2030
12.9.3.1. Digital Therapeutics Market for Substance Use Disorders in North America, 2018-2030
12.9.3.2. Digital Therapeutics Market for Substance Use Disorders in Europe, 2018-2030
12.9.3.3. Digital Therapeutics Market for Substance Use Disorders in Asia-Pacific, 2018-2030
12.9.3.4. Digital Therapeutics Market for Substance Use Disorders in Rest of the World, 2018-2030
 
12.9.4. Digital Therapeutics Market for Cardiovascular Disorders, 2018-2030
12.9.4.1. Digital Therapeutics Market for Cardiovascular Disorders in North America, 2018-2030
12.9.4.2. Digital Therapeutics Market for Cardiovascular Disorders in Europe, 2018-2030
12.9.4.3. Digital Therapeutics Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030
12.9.4.4. Digital Therapeutics Market for Cardiovascular Disorders in Rest of the World, 2018-2030
 
12.9.5. Digital Therapeutics Market for Chronic Pain, 2018-2030
12.9.5.1. Digital Therapeutics Market for Chronic Pain in North America, 2018-2030
12.9.5.2. Digital Therapeutics Market for Chronic Pain in Europe, 2018-2030
12.9.5.3. Digital Therapeutics Market for Chronic Pain in Asia-Pacific, 2018-2030
12.9.5.4. Digital Therapeutics Market for Chronic Pain in Rest of the World, 2018-2030
 
12.9.6. Digital Therapeutics Market for Sleep Disorders, 2018-2030
12.9.6.1. Digital Therapeutics Market for Sleep Disorders in North America, 2018-2030
12.9.6.2. Digital Therapeutics Market for Sleep Disorders in Europe, 2018-2030
12.9.6.3. Digital Therapeutics Market for Sleep Disorders in Asia-Pacific, 2018-2030
12.9.6.4. Digital Therapeutics Market for Sleep Disorders in Rest of the World, 2018-2030
 
12.9.7. Digital Therapeutics Market for Respiratory Disorders, 2018-2030
12.9.7.1. Digital Therapeutics Market for Respiratory Disorders in North America, 2018-2030
12.9.7.2. Digital Therapeutics Market for Respiratory Disorders in Europe, 2018-2030
12.9.7.3. Digital Therapeutics Market for Respiratory Disorders in Asia-Pacific, 2018-2030
12.9.7.4. Digital Therapeutics Market for Respiratory Disorders in Rest of the World, 2018-2030
12.9.8. Digital Therapeutics Market for Neurological Disorders, 2018-2030
12.9.8.1. Digital Therapeutics Market for Neurological Disorders in North America, 2018-2030
12.9.8.2. Digital Therapeutics Market for Neurological Disorders in Europe, 2018-2030
12.9.8.3. Digital Therapeutics Market for Neurological Disorders in Asia-Pacific, 2018-2030
12.9.8.4. Digital Therapeutics Market for Neurological Disorders in Rest of the World, 2018-2030
 
12.9.9. Digital Therapeutics Market for Other Disorders, 2018-2030
12.9.9.1. Digital Therapeutics Market for Other Disorders in North America, 2018-2030
12.9.9.2. Digital Therapeutics Market for Other Disorders in Europe, 2018-2030
12.9.9.3. Digital Therapeutics Market for Other Disorders in Asia-Pacific, 2018-2030
12.9.4.4. Digital Therapeutics Market for Other Disorders in Rest of the World, 2018-2030
 
12.10. Global Digital Monitoring / Diagnostic Solutions Market, 2018-2030
 
12.11. Global Digital Monitoring / Diagnostic Solutions Market: Distribution by Type of Solution
12.11.1. Digital Monitoring / Diagnostic Solutions Market for Standalone Software Applications, 2018-2030
12.11.2. Digital Monitoring / Diagnostic Solutions Market for Standalone Wearable Devices, 2018-2030
12.11.3. Digital Monitoring / Diagnostic Solutions Market for Combination Offerings (Software Application + Device), 2018-2030
12.11.4. Digital Monitoring / Diagnostic Solutions Market for Combination Offerings (Software Application + Wearable Device), 2018-2030
12.11.5. Digital Monitoring / Diagnostic Solutions Market for Other Type of Solutions, 2018-2030
 
12.12. Global Digital Monitoring / Diagnostic Solutions Market: Distribution by Business Model
12.12.1. Digital Monitoring / Diagnostic Solutions Market for B2C Model (Patients), 2018-2030
12.12.2. Digital Monitoring / Diagnostic Solutions Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2018-2030
12.13. Global Monitoring / Diagnostic Solutions Market: Distribution by Geography
12.13.1 Digital Monitoring / Diagnostic Solutions Market in North America, 2018-2030
12.13.1.1 Digital Monitoring / Diagnostic Solutions Market in the US, 2018-2030
12.13.1.2. Digital Monitoring / Diagnostic Solutions Market in Canada, 2018-2030
 
12.13.2 Digital Monitoring / Diagnostic Solutions Market in Europe, 2018-2030
12.13.2.1. Digital Monitoring / Diagnostic Solutions Market in Germany, 2018-2030
12.13.2.2. Digital Monitoring / Diagnostic Solutions Market in France, 2018-2030
12.13.2.3. Digital Monitoring / Diagnostic Solutions Market in Russia, 2018-2030
12.13.2.4. Digital Monitoring / Diagnostic Solutions Market in Italy, 2018-2030
12.13.2.5. Digital Monitoring / Diagnostic Solutions Market in the UK, 2018-2030
12.13.2.6. Digital Monitoring / Diagnostic Solutions Market in Spain, 2018-2030
12.13.2.7. Digital Monitoring / Diagnostic Solutions Market in Rest of Europe, 2018-2030
 
12.13.3. Digital Monitoring / Diagnostic Solutions Market in Asia-Pacific, 2018-2030
12.13.3.1. Digital Monitoring / Diagnostic Solutions Market in China, 2018-2030
12.13.3.2. Digital Monitoring / Diagnostic Solutions Market in Japan, 2018-2030
12.13.3.3. Digital Monitoring / Diagnostic Solutions Market in India, 2018-2030
12.13.3.4. Digital Monitoring / Diagnostic Solutions Market in South Korea, 2018-2030
12.13.3.5. Digital Monitoring / Diagnostic Solutions Market in Australia, 2018-2030
12.13.3.6. Digital Monitoring / Diagnostic Solutions Market in Rest of Asia-Pacific, 2018-2030
 
12.14. Global Monitoring / Diagnostic Solutions Market: Distribution by Therapeutic Area
12.14.1. Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders, 2018-2030
12.14.1.1. Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in North America, 2018-2030
12.14.1.2. Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Europe, 2018-2030
12.14.1.3. Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030
12.14.1.4. Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Rest of the World, 2018-2030
 
12.14.2. Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders, 2018-2030
12.14.2.1. Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in North America, 2018-2030
12.14.2.2. Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Europe, 2018-2030
12.14.2.3. Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Asia-Pacific, 2018-2030
12.14.2.4. Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Rest of the World, 2018-2030
 
12.14.3. Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases, 2018-2030
12.14.3.1. Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in North America, 2018-2030
12.14.3.2. Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Europe, 2018-2030
12.14.3.3. Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Asia-Pacific, 2018-2030
12.14.3.4. Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Rest of the World, 2018-2030
 
12.14.4. Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders, 2018-2030
12.14.4.1. Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in North America, 2018-2030
12.14.4.2. Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Europe, 2018-2030
12.14.4.3. Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Asia-Pacific, 2018-2030
12.14.4.4. Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Rest of the World, 2018-2030
 
12.14.5. Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders, 2018-2030
12.14.5.1. Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in North America, 2018-2030
12.14.5.2. Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Europe, 2018-2030
12.14.5.3. Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Asia-Pacific, 2018-2030
12.14.5.4. Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Rest of the World, 2018-2030
 
12.14.6. Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems, 2018-2030
12.14.6.1. Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in North America, 2018-2030
12.14.6.2. Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Europe, 2018-2030
12.14.6.3. Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Asia-Pacific, 2018-2030
12.14.6.4. Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Rest of the World, 2018-2030
 
12.14.7. Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders, 2018-2030
12.14.7.1. Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in North America, 2018-2030
12.14.7.2. Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Europe, 2018-2030
12.14.7.3. Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Asia-Pacific, 2018-2030
12.14.7.4. Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Rest of the World, 2018-2030
 
12.14.8. Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders, 2018-2030
12.14.8.1. Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in North America, 2018-2030
12.14.8.2. Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Europe, 2018-2030
12.14.8.3. Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Asia-Pacific, 2018-2030
12.14.8.4. Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Rest of the World, 2018-2030
 
12.14.9. Digital Monitoring / Diagnostic Solutions Market for Chronic Disorders, 2018-2030
12.14.9.1. Digital Monitoring / Diagnostic Solutions Market for Other Disorders in North America, 2018-2030
12.14.9.2. Digital Monitoring / Diagnostic Solutions Market for Other Disorders in Europe, 2018-2030
12.14.9.3. Digital Monitoring / Diagnostic Solutions Market for Other Disorders in Asia-Pacific, 2018-2030
12.14.9.4. Digital Monitoring / Diagnostic Solutions Market for Other Disorders in Rest of the World, 2018-2030
 
13. FUTURE OF DIGITAL SOLUTIONS FOR CHRONIC DISEASE MANAGEMENT
13.1. Chapter Overview
13.2. Digital Health Solutions: SWOT Analysis
13.2.1. Strengths
13.2.2. Weaknesses
13.2.3. Opportunities
13.3.4. Threats
13.3. Digital Solutions for Chronic Disorders: Future Opportunities
13.3.1. Increasing Focus on Patient Centric Models
13.3.2. Applicability Across a Variety of Disease Indications
13.3.3. Increasing Emphasis on Real-World Evidence in R&D
13.3.4. Advances in IT and Computing Power to Foster Future Innovation
13.3.5. Rising Future Demand for Digital Solutions
13.4. Concluding Remarks
 
14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Adam Kaufman, Chief Executive Officer, Canary Health
14.3. Amelie Janson, Communications Manager, Voluntis
14.4. Prayat Shah, Co-founder and Vice President, Partnerships, and Reshma Nayak Vice President, Marketing and Communications, Wellthy Therapeutics
14.5. Stephanie Tilenius, Co-Founder and Chief Executive Officer, Vida Health
14.6. Vijay Ravindran, Chief Executive Officer, Floreo
 
15. APPENDIX 1: TABULATED DATA
 
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Digital Health: Google Trends (2008-2018)
Figure 3.2 Internet of Things: Framework
Figure 3.3 Internet of Things: Applications in Healthcare
Figure 3.4 Prescription Digital Therapeutics: Process Map
Figure 3.5 Characteristics of a Digital Therapeutic Program: An Illustration
Figure 3.6 Digital Therapeutics: Google Trends (2008-2018)
Figure 4.1 Digital Therapeutics: Distribution of Industry Players by Year of Establishment
Figure 4.2 Digital Therapeutics: Distribution of Industry Players by Geographical Location
Figure 4.3 Digital Therapeutics: Distribution of Industry Players by Size (Employee Count)
Figure 4.4 Digital Therapeutics: Distribution by Type of Solution
Figure 4.5 Digital Therapeutics: Distribution by Primary Disease Area
Figure 4.6 Digital Therapeutics: Distribution by Therapeutic Area
Figure 4.7 Digital Therapeutics: Distribution by Purpose of Solution
Figure 4.8 Digital Therapeutics: Distribution by Focus of Solution
Figure 4.9 Digital Therapeutics: Distribution by Status of Development
Figure 4.10 Digital Therapeutics: Distribution by Type of Business Model
Figure 4.11 Digital Therapeutics: Grid Analysis
Figure 4.12 Digital Therapeutics: Dot-Plot Analysis for Most Active Players
Figure 4.13 Digital Monitoring / Diagnostic Solutions: Distribution of Industry Players by Year of Establishment
Figure 4.14 Digital Monitoring / Diagnostic Solutions: Distribution of Industry Players by Geographical Location
Figure 4.15 Digital Monitoring / Diagnostic Solutions: Distribution of Industry Players by Size (Employee Count)
Figure 4.16 Digital Monitoring / Diagnostic Solutions: Distribution by Type of Solution
Figure 4.17 Digital Monitoring / Diagnostic Solutions: Distribution by Primary Disease Area
Figure 4.18 Digital Monitoring / Diagnostic Solutions: Distribution by Therapeutic Area
Figure 4.19 Digital Monitoring / Diagnostic Solutions: Distribution by Status of Development
Figure 4.20 Digital Monitoring / Diagnostic Solutions: Grid Analysis
Figure 5.1 2Morrow Programs: Advantages
Figure 5.2 2Morrow: Product Portfolio and Treatment Approach
Figure 5.3 2Morrow Smoking Cessation Program: Top 10 Features Tracked by Participants in Clinical Study
Figure 5.4 Akili Interactive: Core Technologies and Benefits of Digital Products
Figure 5.5 Akili Interactive: Product Portfolio
Figure 5.6 Omada Health: Key Clinical Outcomes of Diabetes Prevention Program
Figure 5.7 Pear Therapeutics: Product Portfolio
Figure 5.8 Pear Therapeutics: Clinical Trial Results of reSET
Figure 5.9 WellDoc: Key Benefits of Diabetes Management Program
Figure 5.10 Wellthy Therapeutics: Diabetes Program
Figure 6.1 AliveCor: Benefits of Kardia
Figure 6.2 Cue: Key Elements of Digital Monitoring / Diagnostic Solution
Figure 6.3 Kinsa: Product Portfolio
Figure 7.1 Digital Therapeutics for Metabolic Disorders: Market Landscape
Figure 7.2 Digital Therapeutics for Mental Health Problems: Market Landscape
Figure 7.3 Digital Therapeutics for Neurological Disorders: Market Landscape
Figure 7.4 Digital Therapeutics for Other Therapeutic Areas: Market Landscape
Figure 8.1 Clinical Trials of Digital Therapeutics: Distribution by Therapeutic Areas
Figure 8.2 Clinical Trials of Digital Therapeutics: Primary Endpoints for Metabolic Disorders
Figure 9.1 Digital Therapeutics: Cumulative Number of Funding Instances, 2007-May-2018
Figure 9.2 Digital Therapeutics: Cumulative Amount Invested, 2007-May-2018 (USD Million)
Figure 9.3 Digital Therapeutics: Distribution of Funding Instances by Type, 2007- May-2018
Figure 9.4 Digital Therapeutics: Distribution of Total Amount Invested by Type of Funding, 2007-May-2018 (USD Million)
Figure 9.5 Digital Therapeutics: Most Active Players in terms of Number of Instances, 2007- May-2018
Figure 9.6 Digital Therapeutics: Most Active Players in terms of Amount Invested, 2007- May-2018 (USD Million)
Figure 9.7 Digital Therapeutics: Most Active Investors in terms of Number of Instances, 2007- May-2018
Figure 9.8 Digital Monitoring / Diagnostic Solutions: Cumulative Number of Funding Instances, 2001- May-2018
Figure 9.9 Digital Monitoring / Diagnostic Solutions: Cumulative Amount Invested, 2001- May-2018 (USD Million)
Figure 9.10 Digital Monitoring / Diagnostic Solutions: Distribution of Funding Instances by Type, 2001-May-2018
Figure 9.11 Digital Monitoring / Diagnostic Solutions: Distribution of Total Amount Invested by Type of Funding, 2001-May-2018 (USD Million)
Figure 9.12 Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Number of Instances, 2001- May-2018
Figure 9.13 Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Amount Invested, 2007- May-2018 (USD Million)
Figure 9.14 Digital Monitoring / Diagnostic Solutions: Most Active Investors in terms of Number of Instances
Figure 10.1 Recent Collaborations: Distribution by Year (2008– May 2018)
Figure 10.2 Recent Collaborations: Distribution by Type of Model
Figure 10.3 Recent Collaborations: Distribution by Type of Model and Year of Collaboration
Figure 10.4 Recent Collaborations: Distribution by Type of Model and Geographical Presence of Companies
Figure 10.5 Recent Collaborations: Most Active Companies
Figure 11.1 Go-to-Market Strategy: Active Commonly Used Social Media Platforms
Figure 11.2 Go-to-Market Strategy: Online / Print Media
Figure 11.3 Go-to-Market Strategy: Pricing Trends
Figure 11.4 Go-to-Market Strategy: Promotional Activities
Figure 12.1 Global Digital Therapeutics Market, 2018-2030 (USD Billion)
Figure 12.2 Digital Therapeutics Market for Standalone Software Applications, 2018-2030 (USD Billion)
Figure 12.3 Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2018-2030 (USD Billion)
Figure 12.4 Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2018-2030 (USD Billion)
Figure 12.5 Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2018-2030 (USD Billion)
Figure 12.6 Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2018-2030 (USD Billion)
Figure 12.7 Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2018-2030 (USD Billion)
Figure 12.8 Digital Therapeutics Market for Other Type of Solutions, 2018-2030 (USD Billion)
Figure 12.9 Digital Therapeutics Market for Medication Replacement Solutions, 2018-2030 (USD Billion)
Figure 12.10 Digital Therapeutics Market for Medication Augmentation Solutions, 2018-2030 (USD Billion)
Figure 12.11 Digital Therapeutics Market for Therapeutic Solutions, 2018-2030 (USD Billion)
Figure 12.12 Digital Therapeutics Market for Preventive Solutions, 2018-2030 (USD Billion)
Figure 12.13 Digital Therapeutics Market for B2C Model (Patients), 2018-2030 (USD Billion)
Figure 12.14 Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2018-2030 (USD Billion)
Figure 12.15 Digital Therapeutics Market in North America, 2018-2030 (USD Billion)
Figure 12.16 Digital Therapeutics Market in the US, 2018-2030 (USD Billion)
Figure 12.17 Digital Therapeutics Market in Canada, 2018-2030 (USD Billion)
Figure 12.18 Digital Therapeutics Market in Europe, 2018-2030 (USD Billion)
Figure 12.19 Digital Therapeutics Market in Germany, 2018-2030 (USD Billion)
Figure 12.20 Digital Therapeutics Market in France, 2018-2030 (USD Billion)
Figure 12.21 Digital Therapeutics Market in Russia, 2018-2030 (USD Billion)
Figure 12.22 Digital Therapeutics Market in Italy, 2018-2030 (USD Billion)
Figure 12.23 Digital Therapeutics Market in the UK, 2018-2030 (USD Billion)
Figure 12.24 Digital Therapeutics  Market in Spain, 2018-2030 (USD Billion)
Figure 12.25 Digital Therapeutics Market in Rest of Europe, 2018-2030 (USD Billion)
Figure 12.26 Digital Therapeutics Market in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.27 Digital Therapeutics Market in China, 2018-2030 (USD Billion)
Figure 12.28 Digital Therapeutics Market in Japan, 2018-2030 (USD Billion)
Figure 12.29 Digital Therapeutics Market in India, 2018-2030 (USD Billion)
Figure 12.30 Digital Therapeutics Market in Australia, 2018-2030 (USD Billion)
Figure 12.31 Digital Therapeutics Market in South Korea, 2018-2030 (USD Billion)
Figure 12.32 Digital Therapeutics Market in Rest of Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.33 Digital Therapeutics Market in Rest of the World, 2018-2030 (USD Billion)
Figure 12.34 Digital Therapeutics Market for Metabolic Disorders, 2018-2030 (USD Billion)
Figure 12.35 Digital Therapeutics Market for Metabolic Disorders in North America, 2018-2030 (USD Billion)
Figure 12.36 Digital Therapeutics Market for Metabolic Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.37 Digital Therapeutics Market for Metabolic Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.38 Digital Therapeutics Market for Metabolic Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.39 Digital Therapeutics Market for Mental Health Problems, 2018-2030 (USD Billion)
Figure 12.40 Digital Therapeutics Market for Mental Health Problems in North America, 2018-2030 (USD Billion)
Figure 12.41 Digital Therapeutics Market for Mental Health Problems in Europe, 2018-2030 (USD Billion)
Figure 12.42 Digital Therapeutics Market for Mental Health Problems in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.43 Digital Therapeutics Market for Mental Health Problems in Rest of the World, 2018-2030 (USD Billion)
Figure 12.44 Digital Therapeutics Market for Substance Use Disorders, 2018-2030 (USD Billion)
Figure 12.45 Digital Therapeutics Market for Substance Use Disorders in North America, 2018-2030 (USD Billion)
Figure 12.46 Digital Therapeutics Market for Substance Use Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.47 Digital Therapeutics Market for Substance Use Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.48 Digital Therapeutics Market for Substance Use Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.49 Digital Therapeutics Market for Cardiovascular Disorders, 2018-2030 (USD Billion)
Figure 12.50 Digital Therapeutics Market for Cardiovascular Disorders in North America, 2018-2030 (USD Billion)
Figure 12.51 Digital Therapeutics Market for Cardiovascular Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.52 Digital Therapeutics Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.53 Digital Therapeutics Market for Cardiovascular Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.54 Digital Therapeutics Market for Chronic Pain, 2018-2030 (USD Billion)
Figure 12.55 Digital Therapeutics Market for Chronic Pain in North America, 2018-2030 (USD Billion)
Figure 12.56 Digital Therapeutics Market for Chronic Pain in Europe, 2018-2030 (USD Billion)
Figure 12.57 Digital Therapeutics Market for Chronic Pain in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.58 Digital Therapeutics Market for Chronic Pain in Rest of the World, 2018-2030 (USD Billion)
Figure 12.59 Digital Therapeutics Market for Sleep Disorders, 2018-2030 (USD Billion)
Figure 12.60 Digital Therapeutics Market for Sleep Disorders in North America, 2018-2030 (USD Billion)
Figure 12.61 Digital Therapeutics Market for Sleep Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.62 Digital Therapeutics Market for Sleep Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.63 Digital Therapeutics Market for Sleep Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.64 Digital Therapeutics Market for Respiratory Disorders, 2018-2030 (USD Billion)
Figure 12.65 Digital Therapeutics Market for Respiratory Disorders in North America, 2018-2030 (USD Billion)
Figure 12.66 Digital Therapeutics Market for Respiratory Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.67 Digital Therapeutics Market for Respiratory Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.68 Digital Therapeutics Market for Respiratory Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.69 Digital Therapeutics Market for Neurological Disorders, 2018-2030 (USD Billion)
Figure 12.70 Digital Therapeutics Market for Neurological Disorders in North America, 2018-2030 (USD Billion)
Figure 12.71 Digital Therapeutics Market for Neurological Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.72 Digital Therapeutics Market for Neurological Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.73 Digital Therapeutics Market for Neurological Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.74 Digital Therapeutics Market for Other Disorders, 2018-2030 (USD Billion)
Figure 12.75 Digital Therapeutics Market for Other Disorders in North America, 2018-2030 (USD Billion)
Figure 12.76 Digital Therapeutics Market for Other Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.77 Digital Therapeutics Market for Other Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.78 Digital Therapeutics Market for Other Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.79 Global Digital Monitoring / Diagnostic Solutions Market, 2018-2030 (USD Billion)
Figure 12.80 Digital Monitoring / Diagnostic Solutions Market for Standalone Software Applications, 2018-2030 (USD Billion)
Figure 12.81 Digital Monitoring / Diagnostic Solutions Market for Standalone Wearable Devices, 2018-2030 (USD Billion)
Figure 12.82 Digital Monitoring / Diagnostic Solutions Market for Combination Offerings (Software Application + Device), 2018-2030 (USD Billion)
Figure 12.83 Digital Monitoring / Diagnostic Solutions Market for Combination Offerings (Software Application + Wearable Device), 2018-2030 (USD Billion)
Figure 12.84 Digital Monitoring / Diagnostic Solutions Market for Other Type of Solutions, 2018-2030 (USD Billion)
Figure 12.85 Digital Monitoring / Diagnostic Solutions Market for B2C Model (Patients), 2018-2030 (USD Billion)
Figure 12.86 Digital Monitoring / Diagnostic Solutions Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2018-2030 (USD Billion)
Figure 12.87 Digital Monitoring / Diagnostic Solutions Market in North America, 2018-2030 (USD Billion)
Figure 12.88 Digital Monitoring / Diagnostic Solutions Market in the US, 2018-2030 (USD Billion)
Figure 12.89 Digital Monitoring / Diagnostic Solutions Market in Canada, 2018-2030 (USD Billion)
Figure 12.90 Digital Monitoring / Diagnostic Solutions Market in Europe, 2018-2030 (USD Billion)
Figure 12.91 Digital Monitoring / Diagnostic Solutions Market in Germany, 2018-2030 (USD Billion)
Figure 12.92 Digital Monitoring / Diagnostic Solutions Market in France, 2018-2030 (USD Billion)
Figure 12.93 Digital Monitoring / Diagnostic Solutions Market in Russia, 2018-2030 (USD Billion)
Figure 12.94 Digital Monitoring / Diagnostic Solutions Market in Italy, 2018-2030 (USD Billion)
Figure 12.95 Digital Monitoring / Diagnostic Solutions Market in the UK, 2018-2030 (USD Billion)
Figure 12.96 Digital Monitoring / Diagnostic Solutions Market in Spain, 2018-2030 (USD Billion)
Figure 12.97 Digital Monitoring / Diagnostic Solutions Market in Rest of Europe, 2018-2030 (USD Billion)
Figure 12.98 Digital Monitoring / Diagnostic Solutions Market in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.99 Digital Monitoring / Diagnostic Solutions Market in China, 2018-2030 (USD Billion)
Figure 12.100 Digital Monitoring / Diagnostic Solutions Market in Japan, 2018-2030 (USD Billion)
Figure 12.101 Digital Monitoring / Diagnostic Solutions Market in India, 2018-2030 (USD Billion)
Figure 12.102 Digital Monitoring / Diagnostic Solutions Market in South Korea, 2018-2030 (USD Billion)
Figure 12.103 Digital Monitoring / Diagnostic Solutions Market in Australia, 2018-2030 (USD Billion)
Figure 12.104 Digital Monitoring / Diagnostic Solutions Market in Rest of Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.105 Digital Monitoring / Diagnostic Solutions Market in Rest of the World, 2018-2030 (USD Billion)
Figure 12.106 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders, 2018-2030 (USD Billion)
Figure 12.107 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in North America, 2018-2030 (USD Billion)
Figure 12.108 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.109 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.110 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.111 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders, 2018-2030 (USD Billion)
Figure 12.112 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in North America, 2018-2030 (USD Billion)
Figure 12.113 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.114 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.115 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.116 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases, 2018-2030 (USD Billion)
Figure 12.117 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in North America, 2018-2030 (USD Billion)
Figure 12.118 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Europe, 2018-2030 (USD Billion)
Figure 12.119 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.120 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Rest of the World, 2018-2030 (USD Billion)
Figure 12.121 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders, 2018-2030 (USD Billion)
Figure 12.122 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in North America, 2018-2030 (USD Billion)
Figure 12.123 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.124 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.125 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.126 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders, 2018-2030 (USD Billion)
Figure 12.127 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in North America, 2018-2030 (USD Billion)
Figure 12.128 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.129 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.130 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.131 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems, 2018-2030 (USD Billion)
Figure 12.132 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in North America, 2018-2030 (USD Billion)
Figure 12.133 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Europe, 2018-2030 (USD Billion)
Figure 12.134 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.135 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Rest of the World, 2018-2030 (USD Billion)
Figure 12.136 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders, 2018-2030 (USD Billion)
Figure 12.137 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in North America, 2018-2030 (USD Billion)
Figure 12.138 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.139 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.140 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.141 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders, 2018-2030 (USD Billion)
Figure 12.142 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in North America, 2018-2030 (USD Billion)
Figure 12.143 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.144 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 12.145 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 12.146 Digital Monitoring / Diagnostic Solutions Market for Other Disorders, 2018-2030 (USD Billion)
Figure 12.147 Digital Monitoring / Diagnostic Solutions Market for Other Disorders in North America, 2018-2030 (USD Billion)
Figure 12.148 Digital Monitoring / Diagnostic Solutions Market for Other Disorders in Europe, 2018-2030 (USD Billion)
Figure 12.149 Digital Monitoring / Diagnostic Solutions Market for Other Disorders in Asia-Pacific, 2018-2030 (USD Billion)Figure 12.150 Digital Monitoring / Diagnostic Solutions Market for Other Chronic Disorders in Rest of the World, 2018-2030 (USD Billion)

List of Tables

Table 4.1 Digital Therapeutics: List of Solutions
Table 4.2 Digital Therapeutics: Overview of the Type of Solutions 
Table 4.3 Digital Therapeutics: Information on Key Therapeutic Areas, Focus of Solution, Purpose of Solution and Stage of Development
Table 4.4 Digital Monitoring / Diagnostic Solutions: List of Solutions
Table 4.5 Digital Monitoring / Diagnostic Solutions: Overview of the Type of Solutions
Table 4.6 Digital Monitoring / Diagnostic Solutions: Information on Primary Disease Area, Therapeutic Area and Status of Development
Table 5.1 2Morrow: Key Highlights
Table 5.2 2Morrow: Recent Developments and Future Outlook
Table 5.3 Akili Interactive: Key Highlights
Table 5.4 Akili Interactive: Recent Developments and Future Outlook
Table 5.5 Canary Health: Key Highlights
Table 5.6 Canary Health: Recent Developments and Future Outlook
Table 5.7 Floreo: Key Highlights
Table 5.8 Floreo: Recent Developments and Future Outlook
Table 5.9 Omada Health: Key Highlights
Table 5.10 Omada Health: Recent Developments and Future Outlook
Table 5.11 Pear Therapeutics: Key Highlights
Table 5.12 Pear Therapeutics: Recent Developments and Future Outlook
Table 5.13 Vida Health: Key Highlights
Table 5.14 Vida Health: Recent Developments and Future Outlook
Table 5.15 WellDoc: Key Highlights
Table 5.16 WellDoc: Recent Developments and Future Outlook
Table 5.17 Wellthy Therapeutics: Key Highlights
Table 5.18 Wellthy Therapeutics: Recent Developments and Future Outlook
Table 6.1 AliveCor: Key Highlights
Table 6.2 AliveCor: Recent Developments and Future Outlook
Table 6.3 BioSerenity: Key Highlights
Table 6.4 BioSerenity: Recent Developments and Future Outlook
Table 6.5 AliveCor: Key Highlights
Table 6.6 Kinsa: Key Highlights
Table 6.7 Kinsa: Recent Developments and Future Outlook
Table 6.8 Voluntis: Key Highlights
Table 6.9 Voluntis: Recent Developments and Future Outlook
Table 7.1 Digital Therapeutics for Metabolic Disorders: Product Competitiveness Analysis
Table 7.2 Digital Therapeutics for Mental Health Problems: Product Competitiveness Analysis
Table 7.3 Digital Therapeutics for Neurological Disorders: Product Competitiveness Analysis
Table 8.1 Digital Therapeutics: List of Clinical Trials (Details on Trial Title, NCT Number, Therapeutic Area, Sponsor, Collaborator and Trial Duration)
Table 8.2 Digital Therapeutics: List of Clinical Trials (Details on Primary Purpose, Primary and Secondary End- Points, Trial Location and Study Outcomes)
Table 9.1 Digital Therapeutics: Funding and Investments, 2007-2018
Table 9.2 Digital Therapeutics: Summary of Investments
Table 9.3 Digital Monitoring / Diagnostic Solutions: Funding and Investments, 2007- May-2018
Table 9.4 Digital Monitoring / Diagnostic Solutions: Summary of Investments
Table 10.1 Digital Therapeutics and Monitoring / Diagnostic Solutions: List of Partnerships
Table 11.1 Digital Therapeutics: Summary of Marketing Strategies
Table 11.2 Digital Therapeutics: Pricing Models
Table 12.1 Global Digital Therapeutics Market: Distribution Market: Distribution of Available / Under Development Solutions by Therapeutic Areas, % Share
Table 12.2 Global Digital Monitoring & Diagnostic Solutions Market: Distribution of Available / Under Development Solutions by Therapeutic Area, % Share
Table 12.3 Global Digital Therapeutics Market: Distribution of Available / Under Development Solutions by Type of Solutions, % Share
Table 12.4 Global Digital Monitoring & Diagnostic Solutions Market: Distribution of Available / Under Development Solutions by Type of Solutions, % Share
Table 12.5 Global Digital Therapeutics Market: Distribution of Available / Under Development Solutions by Purpose of Solution, % Share
Table 12.6 Global Digital Therapeutics Market: Distribution of Available / Under Development Solutions by Focus of Solution, % Share
Table 12.7 Global Digital Health Solutions Market: Distribution of Available / Under Development Solutions by Marketing Channel, % Share 
Table 12.8 Global Digital Health Solutions Market: Distribution by Regions (2017, 2030), % Share
Table 15.1 Digital Therapeutics: Distribution of Industry Players by Year of Establishment
Table 15.2 Digital Therapeutics: Distribution of Industry Players by Geographical Location
Table 15.3 Digital Therapeutics: Distribution of Industry Players by Size (Employee Count)
Table 15.4 Digital Therapeutics: Distribution by Type of Solution
Table 15.5 Digital Therapeutics: Distribution by Primary Disease Area
Table 15.6 Digital Therapeutics: Distribution by Key Therapeutic Area
Table 15.7 Digital Therapeutics: Distribution by Purpose of Solution
Table 15.8 Digital Therapeutics: Distribution by Focus of Solution
Table 15.9 Digital Therapeutics: Distribution by Status of Development
Table 15.10 Digital Therapeutics: Distribution by Type of Business Model
Table 15.11 Digital Monitoring / Diagnostic Solutions: Distribution of Industry Players by Year of Establishment
Table 15.12 Digital Monitoring / Diagnostic Solutions: Distribution of Industry Players by Geographical Location
Table 15.13 Digital Monitoring / Diagnostic Solutions: Distribution of Industry Players by Size (Employee Count)
Table 15.14 Digital Monitoring / Diagnostic Solutions: Distribution by Type of Solution
Table 15.15 Digital Monitoring / Diagnostic Solutions: Distribution by Primary Disease Area
Table 15.16 Digital Monitoring / Diagnostic Solutions: Distribution by Key Therapeutic Area
Table 15.17 Digital Monitoring / Diagnostic Solutions: Distribution by Status of Development
Table 15.18 Clinical Trials for Digital Therapeutics: Distribution by Therapeutic Areas
Table 15.19 Digital Therapeutics: Cumulative Number of Funding Instances, 2007 – May-2018
Table 15.20 Digital Therapeutics: Cumulative Amount Invested, 2007- May-2018 (USD Million)
Table 15.21 Digital Therapeutics: Distribution of Funding Instances by Type, 2007- May-2018
Table 15.22 Digital Therapeutics: Distribution of Total Amount Invested by Type of Funding, 2007- May-2018 (USD Million)
Table 15.23 Digital Therapeutics: Most Active Players in terms of Number of Instances, 2007- May-2018
Table 15.24 Digital Therapeutics: Most Active Players in terms of Amount Invested, 2007- May-2018 (USD Million)
Table 15.25 Digital Therapeutics: Most Active Investors in terms of Number of Instances, 2007- May-2018
Table 15.26 Digital Monitoring / Diagnostic Solutions: Cumulative Number of Funding Instances, 2001- May-2018
Table 15.27 Digital Monitoring / Diagnostic Solutions: Cumulative Amount Invested, 2001- May-2018 (USD Million)
Table 15.28 Digital Monitoring / Diagnostic Solutions: Distribution of Funding Instance by Type, 2001- May-2018
Table 15.29 Digital Monitoring / Diagnostic Solutions: Distribution of Total Amount Invested by Type of Funding, 2001- May-2018 (USD Million)
Table 15.30 Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Number of Instances, 2001- May-2018
Table 15.31 Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Amount Invested, 2007- May-2018 (USD Million)
Table 15.32 Digital Monitoring / Diagnostic Solutions: Most Active Investors in terms of Number of Instances
Table 15.33 Recent Collaborations: Distribution by Year (2008 – May 2018)
Table 15.34 Recent Collaborations: Distribution by Type of Model
Table 15.35 Recent Collaborations: Distribution by Type of Model and Year of Collaboration
Table 15.36 Recent Collaborations: Distribution by Type of Model and Geographical Presence of Companies
Table 15.37 Recent Collaborations: Most Active Companies
Table 15.38 Digital Therapeutics: Pricing Trend
Table 15.39 Global Digital Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.40 Digital Therapeutics Market for Standalone Software Applications, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.41 Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.42 Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.43 Digital Therapeutics Market for Combination Offerings (Software Application + Device), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.44 Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.45 Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.46 Digital Therapeutics Market for Other Type of Solutions, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.47 Digital Therapeutics Market for Medication Replacement Solutions, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.48 Digital Therapeutics Market for Medication Augmentation Solutions, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.49 Digital Therapeutics Market for Therapeutic Solutions, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.50 Digital Therapeutics Market for Preventive Solutions, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.51 Digital Therapeutics Market for B2C Model (Patients), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.52 Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.53 Digital Therapeutics Market in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.54 Digital Therapeutics Market in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.55 Digital Therapeutics Market in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.56 Digital Therapeutics Market in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.57 Digital Therapeutics Market in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.58 Digital Therapeutics Market in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.59 Digital Therapeutics Market in Russia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.60 Digital Therapeutics Market in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.61 Digital Therapeutics Market in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.62 Digital Therapeutics Market in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.63 Digital Therapeutics Market in Rest of Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.64 Digital Therapeutics Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.65 Digital Therapeutics Market in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.66 Digital Therapeutics Market in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.67 Digital Therapeutics Market in India, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.68 Digital Therapeutics Market in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.69 Digital Therapeutics Market in South Korea, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.70 Digital Therapeutics Market in Rest of Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.71 Digital Therapeutics Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.72 Digital Therapeutics Market for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.73 Digital Therapeutics Market for Metabolic Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.74 Digital Therapeutics Market for Metabolic Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.75 Digital Therapeutics Market for Metabolic Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.76 Digital Therapeutics Market for Metabolic Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.77 Digital Therapeutics Market for Mental Health Problems, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.78 Digital Therapeutics Market for Mental Health Problems in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.79 Digital Therapeutics Market for Mental Health Problems in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.80 Digital Therapeutics Market for Mental Health Problems in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.81 Digital Therapeutics Market for Mental Health Problems in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.82 Digital Therapeutics Market for Substance Use Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.83 Digital Therapeutics Market for Substance Use Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.84 Digital Therapeutics Market for Substance Use Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.85 Digital Therapeutics Market for Substance Use Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.86 Digital Therapeutics Market for Substance Use Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.87 Digital Therapeutics Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.88 Digital Therapeutics Market for Cardiovascular Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.89 Digital Therapeutics Market for Cardiovascular Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.90 Digital Therapeutics Market for Cardiovascular Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.91 Digital Therapeutics Market for Cardiovascular Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.92 Digital Therapeutics Market for Chronic Pain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.93 Digital Therapeutics Market for Chronic Pain in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.94 Digital Therapeutics Market for Chronic Pain in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.95 Digital Therapeutics Market for Chronic Pain in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.96 Digital Therapeutics Market for Chronic Pain in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.97 Digital Therapeutics Market for Sleep Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.98 Digital Therapeutics Market for Sleep Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.99 Digital Therapeutics Market for Sleep Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.100 Digital Therapeutics Market for Sleep Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.101 Digital Therapeutics Market for Sleep Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.102 Digital Therapeutics Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.103 Digital Therapeutics Market for Respiratory Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.104 Digital Therapeutics Market for Respiratory Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.105 Digital Therapeutics Market for Respiratory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.106 Digital Therapeutics Market for Respiratory Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.107 Digital Therapeutics Market for Neurological Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.108 Digital Therapeutics Market for Neurological Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.109 Digital Therapeutics Market for Neurological Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.110 Digital Therapeutics Market for Neurological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.111 Digital Therapeutics Market for Neurological Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.112 Digital Therapeutics Market for Other Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.113 Digital Therapeutics Market for Other Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.114 Digital Therapeutics Market for Other Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.115 Digital Therapeutics Market for Other Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.116 Digital Therapeutics Market for Other Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.117 Global Digital Monitoring / Diagnostic Solutions Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.118 Digital Monitoring / Diagnostic Solutions Market for Standalone Software Applications, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.119 Digital Monitoring / Diagnostic Solutions Market for Standalone Wearable Devices, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.120 Digital Monitoring / Diagnostic Solutions Market for Combination Offerings (Software Application + Device), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.121 Digital Monitoring / Diagnostic Solutions Market for Combination Offerings (Software Application + Wearable Device), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.122 Digital Monitoring / Diagnostic Solutions Market for Other Type of Solutions, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.123 Digital Monitoring / Diagnostic Solutions Market for B2C Model (Patients), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.124 Digital Monitoring / Diagnostic Solutions Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.125 Digital Monitoring / Diagnostic Solutions Market in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.126 Digital Monitoring / Diagnostic Solutions Market in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.127 Digital Monitoring / Diagnostic Solutions Market in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.128 Digital Monitoring / Diagnostic Solutions Market in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.129 Digital Monitoring / Diagnostic Solutions Market in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.130 Digital Monitoring / Diagnostic Solutions Market in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.131 Digital Monitoring / Diagnostic Solutions Market in Russia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.132 Digital Monitoring / Diagnostic Solutions Market in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.133 Digital Monitoring / Diagnostic Solutions Market in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.134 Digital Monitoring / Diagnostic Solutions Market in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.135 Digital Monitoring / Diagnostic Solutions Market in Rest of Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.136 Digital Monitoring / Diagnostic Solutions Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.137 Digital Monitoring / Diagnostic Solutions Market in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.138 Digital Monitoring / Diagnostic Solutions Market in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.139 Digital Monitoring / Diagnostic Solutions Market in India, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.140 Digital Monitoring / Diagnostic Solutions Market in South Korea, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.141 Digital Monitoring / Diagnostic Solutions Market in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.142 Digital Monitoring / Diagnostic Solutions Market in Rest of Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.143 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.144 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.145 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.146 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.147 Digital Monitoring / Diagnostic Solutions Market for Cardiovascular Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.148 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.149 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.150 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.151 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.152 Digital Monitoring / Diagnostic Solutions Market for Metabolic Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.153 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.154 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.155 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.156 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.157 Digital Monitoring / Diagnostic Solutions Market for Infectious Diseases in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.158 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.159 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.160 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.161 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.162 Digital Monitoring / Diagnostic Solutions Market for Respiratory Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.163 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.164 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.165 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.166 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.167 Digital Monitoring / Diagnostic Solutions Market for Neurological Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.168 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.169 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.170 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.171 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.172 Digital Monitoring / Diagnostic Solutions Market for Mental Health Problems in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.173 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.174 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.175 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.176 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.177 Digital Monitoring / Diagnostic Solutions Market for Substance Use Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.178 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.179 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.180 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.181 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.182 Digital Monitoring / Diagnostic Solutions Market for Oncological Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.183 Digital Monitoring / Diagnostic Solutions Market for Other Chronic Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.184 Digital Monitoring / Diagnostic Solutions Market for Other Chronic Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.185 Digital Monitoring / Diagnostic Solutions Market for Other Chronic Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)Table 15.186 Digital Monitoring / Diagnostic Solutions Market for Other Chronic Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 15.187 Digital Monitoring / Diagnostic Solutions Market for Other Chronic Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)

List of Companies

The following companies and organizations have been mentioned in the report.

  1. 2Morrow
  2. 3M Ventures
  3. 500 Startups
  4. 5AM Ventures
  5. 7wire Ventures
  6. Abbott
  7. AbbVie
  8. Aberdare Ventures
  9. Academy of Managed Care Pharmacists
  10. ACC
  11. Accel Diagnostics
  12. Accenture
  13. Adage Capital Management
  14. Adams Street Partners
  15. Advanced Circulatory Systems
  16. Advancit Capital
  17. Aetna
  18. Airbus
  19. Akili Interactive
  20. Akron Children's Hospital
  21. Alexandria Venture Investments
  22. AliveCor
  23. Allen & Company
  24. AltaMed
  25. AME Cloud Partners
  26. American Diabetes Association
  27. American Investment Holdings
  28. American Society of Mechanical Engineers
  29. American Telemedicine Association
  30. Amgen Venture
  31. Andreessen Horowitz
  32. Anorak Ventures
  33. Anteo Diagnostics
  34. Anyline
  35. Aperture Venture Partners
  36. Aplastic Anemia & MDS International Foundation
  37. Apollo Hospitals
  38. Apple
  39. AppliedVR
  40. Arboretum Ventures
  41. Areta Health
  42. Arthritis New Zealand
  43. Arthro Therapeutics
  44. Ascensia Diabetes Care
  45. Ascension’s Brighton Center for Recovery
  46. Aspect Ventures
  47. Asthma and Allergy Foundation of America
  48. AstraZeneca
  49. AT&T
  50. Athelas
  51. Baillie Gifford
  52. Beaumont Hospital
  53. Becton Dickinson
  54. Beehive Holdings
  55. BEENEXT
  56. BeHealth Solutions
  57. Beneufit
  58. Berger & Moore Advisors
  59. Berklee's Institute for Creative Entrepreneurship
  60. Bessemer Venture Partners
  61. Better Therapeutics
  62. Betterise Health Tech
  63. Beurer
  64. Big Health
  65. Bigfoot Biomedical 
  66. Bigpoint
  67. Bioepic
  68. Biomark
  69. BioSerenity
  70. BioTrak Therapeutics
  71. Biotricity
  72. Bioventures Investors
  73. Birla Institute of Technology and Science
  74. bLife
  75. Bloom Burton
  76. Blue Mesa Health
  77. Blue Spark Technologies
  78. Blueprint Health
  79. Bodyport
  80. Boston Medical Center
  81. Bpifrance Large Venture
  82. BrainCheck
  83. Breyer Capital
  84. Bridge Builders Collaborative
  85. Broadway Video Ventures
  86. Brooklands Capital Strategies
  87. Burrill & Company
  88. Burston
  89. C. Illies
  90. Caffeinated Capital
  91. California HealthCare Foundation
  92. Cambia Health Solutions
  93. Canaan Partners
  94. Canary Foundation
  95. Canary Health
  96. Cancer Research Collaboration (CRC)
  97. Canepa Advanced Healthcare Fund
  98. Canvas Ventures
  99. CapDecisif Management
  100. Capricorn ICT Arkiv
  101. CareFirst
  102. Carrot Health
  103. Castlight Health
  104. Cavendish Global
  105. CAVU Venture Partners
  106. Cedars-Sinai Medical Center
  107. Celebrate the Children
  108. CellScope
  109. Center for Autism Research (CAR)
  110. Center for Managing Chronic Disease, University of Michigan
  111. Center for the Advancement of Science in Space
  112. Central Illinois Angels
  113. Centria Healthcare Autism Services
  114. Chicago Ventures
  115. Children's Hospital of Philadelphia
  116. Cigna
  117. CIS Agriferts
  118. Civilization Ventures
  119. Claritas MindSciences
  120. Click Therapeutics
  121. CM-CIC Innovation
  122. Colgate-Palmolive
  123. COLOPL VR Fund
  124. Columbia University Medical Center
  125. Community College System of New Hampshire
  126. Connecticut Innovations
  127. CoreHealth Technologies
  128. Correlation Ventures
  129. COWEN
  130. CPS Capital Group
  131. CRCM Ventures
  132. Creandum
  133. Cue
  134. Currae Healthtech
  135. Cyrcadia Health
  136. DAK-Gesundheit
  137. Dartmouth College
  138. Data Collective
  139. Dataiku
  140. DCM
  141. Deerfield Management
  142. Delivering Scientific Innovation for Autism
  143. Dendera Ventures
  144. Dentsu Ventures
  145. Department of Veteran Affairs
  146. Dermal Clinic
  147. Dexcom
  148. Diasend
  149. Digitalis
  150. Digithera
  151. dLife
  152. Draper Fisher Jurvetson
  153. dRx Capital
  154. Dthera Sciences
  155. Echo Health Ventures
  156. eClinical Works
  157. Eco-Fusion
  158. EDBI
  159. Elevation Capital
  160. Ellume 
  161. Emory University
  162. Empatica
  163. Empire Capital Partners
  164. Endeavor Catalyst
  165. Endotronix
  166. Essex Woodlands
  167. European School on Interdisciplinary Tinnitus Research
  168. Eva Ventures
  169. Excel Venture Management
  170. Facebook
  171. Felicis Ventures
  172. FireStarter Fund
  173. FirstMark Capital
  174. Fit4D
  175. FitBit
  176. Flare Capital Partners
  177. Flatiron Investors
  178. Floodgate
  179. Floreo
  180. Florida Hospital
  181. Flying Health
  182. Force Over Mass Capital
  183. Ford Motor Company
  184. Forward Partners
  185. Founder Collective
  186. Founders Fund
  187. Fred Hutchinson Cancer Research Center
  188. Freelands Ventures
  189. Fruit Street
  190. Fuerst Technology Innovations
  191. GAIA
  192. GC VR Tracker Fund
  193. GE Ventures
  194. Genentech
  195. General Catalyst
  196. George Washington University School of Medicine
  197. Georgian Partners
  198. GlaxoSmithKline
  199. Global to Local
  200. Glooko
  201. GluSense
  202. GNS Healthcare
  203. Greycroft
  204. GrowX Venture Management
  205. GSR Ventures
  206. Hanmi IT
  207. Harbor Pacific Capital
  208. Harrison Metal
  209. Health Care Originals
  210. HealthReveal
  211. HealthSlate
  212. HealthTap
  213. HealthX Ventures
  214. Healthy Trucking Association of America
  215. Heart Foundation
  216. HelloFresh
  217. Highmark Health
  218. High-Tech Gründerfonds
  219. Hikma Ventures
  220. Hint
  221. Hintsa Performance
  222. Hospices Civils de Lyon
  223. Hudson River Capital Partners
  224. Human API
  225. Humana
  226. Hyde Park Angels
  227. I2A Fund
  228. iBionext 
  229. IBM
  230. Idinvest Partners
  231. IEEE
  232. iHealth Lab
  233. IIFL Select Equity Fund
  234. i-Mercury Capital
  235. Immortalana
  236. iMotions
  237. Impact First Investments
  238. Incos Invest
  239. Index Ventures
  240. Initialized Capital
  241. Innogest Capital
  242. INNOTHERA
  243. Innovate Health Tech NYC
  244. Innovation Capital
  245. Innovation Works
  246. Innovationsstarter Fonds Hamburg
  247. Institut de la Vision
  248. Insulet
  249. Intel Capital
  250. Intermountain Healthcare
  251. International Finance Corporation (IFC)
  252. InterVest
  253. Invitalia Ventures
  254. iSeed Ventures
  255. iSono Health
  256. Israel Innovation Authority
  257. Itochu
  258. JamJar Investments
  259. Janssen Research & Development
  260. JAZZ Venture Partners
  261. Jett Capital Advisors
  262. John P. McGovern Museum of Health and Medical Science
  263. Johns Hopkins School of Hygiene and Public Health
  264. Johnson & Johnson Innovation
  265. Joslin Diabetes Center
  266. Joyable
  267. Jumpstart Ventures
  268. Juvenile Diabetes Research Foundation T1D fund
  269. Kaia Health
  270. Kaiser Permanente Ventures
  271. Kapor Capital
  272. Karuna Labs
  273. Khosla Ventures
  274. King's College London
  275. Kinnevik
  276. Kinsa
  277. Kleiner Perkins Caufield & Byers
  278. Kurbo Health
  279. Kurma Diagnostics
  280. Kyma Medical Technologies
  281. Landmark Benefits
  282. Lark Health
  283. LB Investment
  284. LBO France
  285. Leman Micro Devices
  286. LEO Innovation Lab
  287. Lief Therapeutics
  288. Life Sciences Discovery Fund
  289. LifeForce Capital
  290. Lifeforce Ventures
  291. Lifeline Biotechnologies
  292. Lifeline Ventures
  293. LifeScan
  294. Lifespot Health
  295. LifeWatch
  296. LifeWave Biomedical
  297. Lightspeed Venture Partners
  298. LindaCare
  299. LinkedIn
  300. Liquid 2 Ventures
  301. Livongo Health
  302. Louisiana Department of Health
  303. Lumira Capital
  304. Lund University
  305. Lux Capital
  306. M Ventures
  307. M12
  308. m8 Capital
  309. Magellan Health
  310. Manipal Education & Medical Group
  311. MAP Health Management
  312. Maryland Technology Development Corporation (TEDCO)
  313. Massachusetts General Hospital
  314. Max Healthcare
  315. Mayfield Fund
  316. Mayo Clinic
  317. Medelinked
  318. Medtronic
  319. Melon Health
  320. Merck
  321. Meru Health
  322. mHealth Technologies
  323. Mid-Atlantic Telehealth Resource Center 
  324. Millar
  325. Ministry of Health, Manatu Hauora
  326. MIT Hacking Medicine
  327. Mobio Technologies
  328. Montage Ventures
  329. Murray-Bertron
  330. mySugr
  331. Naluri Hidup
  332. Nanobiosym Diagnostics
  333. Nanon
  334. NantHealth
  335. National Aeronautics and Space Administration
  336. National Cancer Institute
  337. National Institute of Biomedical Imaging and Bioengineering
  338. National Institute of Diabetes and Digestive and Kidney Diseases
  339. National Institute of Mental Health and Neuro Sciences
  340. National Institute on Drug Abuse (NIDA)
  341. National Institutes of Health
  342. National Multiple Sclerosis Society
  343. Nemaura Medical
  344. NeuroCure
  345. NeuroMetrix
  346. Neurotrack
  347. New Enterprise Associates
  348. New Mexico Retiree Health Care Authority (NMRHCA)
  349. New World Ventures
  350. Newtopia
  351. Nexeon MedSystems
  352. Nike
  353. Nimbus Synergies
  354. NODEHealth
  355. Nokia Growth Partners
  356. Noom
  357. North Texas Angel Network
  358. North York General Hospital
  359. Northwell Ventures
  360. Norwest Venture Partners
  361. Norwich Ventures
  362. Novant Health
  363. Novartis
  364. Novo Nordisk
  365. Nueon
  366. Nutrino
  367. Obvious Ventures
  368. Octopus Ventures
  369. Oklahoma Life Science Fund
  370. Omada Health
  371. Omega Diagnostics
  372. Omron Healthcare
  373. Oncology Care Home Health
  374. Onduo
  375. Ontario Telemedicine Network
  376. Open Medicine Institute
  377. Oracle
  378. OSF Ventures
  379. Otsuka Pharmaceutical
  380. Oxford Academic Health Science Network
  381. Oxford Finance
  382. Pallasite Ventures
  383. Palo Alto Medical Foundation
  384. Parasail Health
  385. Partners in Health
  386. PatientsLikeMe
  387. Pear Therapeutics
  388. Personal Health Solutions
  389. Pfizer
  390. Philips
  391. Pierre Fabre
  392. Pinterest
  393. Pittsburgh Life Sciences Greenhouse
  394. Pixie Scientific
  395. Playground Global
  396. PMV
  397. Podimetrics
  398. POPS! Diabetes Care
  399. Premera Blue Cross
  400. Presence Capital
  401. Prestige Health Choice
  402. Preventice Solutions
  403. Pritzker Group Venture Capital
  404. Profil Institute
  405. Promus Ventures
  406. Propeller Health
  407. Proteus Digital Health
  408. Provenance Venture Forum
  409. Providence Health & Services
  410. Purdue University
  411. PureTech Health
  412. Qardio
  413. Qiming Venture Partners
  414. Qualcomm Ventures
  415. Quinze-Vingts National Ophthalmology Hospital
  416. Quotas Beteiligungs
  417. R7 Partners
  418. RB Investments
  419. Reaktor Ventures
  420. Real Appeal
  421. Recruit Strategic Partners
  422. RedBrick Health
  423. Redmile Group
  424. Reflectance Medical
  425. ResApp Health
  426. Research Foundation for The State University of New York
  427. Research Society for The Study of Diabetes in India (RSSDI)
  428. Restore Health
  429. Rethink Impact
  430. Retina Foundation of the Southwest
  431. Retrofit
  432. Revon Systems
  433. Rewire
  434. Roche
  435. Rock Health
  436. R-Pharm
  437. RRE Ventures
  438. Rwandan Ministry of Health & National Reference Laboratory
  439. Rx.Health
  440. S.R. One
  441. Safeguard Scientifics
  442. Samsung
  443. Sandoz
  444. Sanitas
  445. Sano Intelligence
  446. Sanofi
  447. Sapphire Ventures
  448. Schoolhouse Partners
  449. SciFi VC
  450. Scrum Ventures
  451. Selfridges
  452. Sennheiser
  453. Sequoia Capital
  454. Servier
  455. ShapeUp
  456. Sherpa Capital
  457. Shire
  458. Signia Venture Partners
  459. Silicon Valley Bank
  460. Sino Portfolio International
  461. Siren Care
  462. Slow Ventures
  463. Social Capital
  464. Solera Health
  465. Somatix
  466. Sonormed
  467. SOS Ventures
  468. Sozo Ventures
  469. Sparo
  470. Spectrum Equity
  471. Spire
  472. SportsWareOnLine
  473. Spotify
  474. Spring Ridge Ventures
  475. St. Joseph's Care Group
  476. St. Jude Medical
  477. St. Luke's Health System
  478. St. Michael's Hospital
  479. STADA
  480. Stanford University
  481. Stanley Park Ventures
  482. Startup Funding Club
  483. StartUp Health
  484. Steelcase
  485. Sunovion Pharmaceuticals
  486. Sutter Health
  487. SV Life Sciences
  488. Sweet Capital
  489. Swiss Re
  490. Synovation Medical Group
  491. Tactio Health Group
  492. Teladoc
  493. Telcare
  494. Telefonica
  495. Temasek Holdings
  496. The Carlyle Group
  497. The Chernin Group
  498. The Robotics Hub
  499. The Sync Project
  500. The Valley Fund
  501. The Venture Reality Fund
  502. The Vertical Group
  503. Thrive Capital
  504. Tilak Healthcare
  505. Tower Capital Partners
  506. TransLink Capital
  507. TreeHouse Health
  508. TriplePoint Capital
  509. True Ventures
  510. True Wealth Ventures
  511. Turnaround Health
  512. Twine Health
  513. Twitter
  514. U.S.Venture Partners
  515. uHealth Australia
  516. Uncork Capital
  517. UniQuest
  518. United Healthcare
  519. University Hospitals Leuven (UZ Leuven)
  520. University Medical Center Goettingen
  521. University of Bern
  522. University of Calgary
  523. University of California San Francisco
  524. University of Hamburg
  525. University of London
  526. University of Lubeck
  527. University of Maryland
  528. University of Massachusetts Medical School
  529. University of Michigan
  530. University of Missouri
  531. University of Nebraska
  532. University of North Carolina
  533. University of Oxford
  534. University of Queensland
  535. University of Rochester
  536. University of Texas at Dallas
  537. University of Texas Southwestern Medical School 
  538. University of Washington
  539. UPMC Enterprises
  540. Valeritas Holdings
  541. Vanguard Medical Group
  542. Venrock
  543. Verily Life Sciences
  544. Vertical Group
  545. Vesalius Biocapital Partners
  546. Vheda Health
  547. Vida Health 
  548. Vimeo
  549. Virgin Atlantic
  550. Virta Health
  551. VirtualScopics
  552. Vital Art and Science
  553. Vivid Vision
  554. VNR Vignana Jyothi Institute of Engineering and Technology
  555. Voluntis
  556. Wake Forest University
  557. Wanxiang America
  558. Washington University School of Medicine 
  559. Welkin Health
  560. WellDoc
  561. Wellthy Therapeutics
  562. Welltrinsic Sleep Network
  563. West Coast Primary Health Organization
  564. William Morris Endeavor
  565. William Osler Health System
  566. Windham Venture Partners
  567. Withings
  568. Workit Health
  569. World Health Organization
  570. XING
  571. Xtreme Labs
  572. Y Combinator
  573. Yale University
  574. YPSOMED
  575. Zaffre Investments
  576. Zoll Medical
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 3,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com